Prevalence of the Apolipoprotein E Arg145Cys Dyslipidemia At-Risk Polymorphism in African-Derived Populations
Open accessAbstract
Apolipoprotein E, a protein component of blood lipid particles, plays an important role in lipid transport. Different mutations in the apolipoprotein E gene have been associated with various clinical phenotypes. In an initiated study of Qataris, we observed that 17% of the African-derived genetic subgroup were heterozygotes for a rare Arg145Cys (R145C) variant that functions as a dominant trait with incomplete penetrance associated with type III hyperlipoproteinemia. On the basis of this observation, we hypothesized that the R145C polymorphism might be common in African-derived populations. The prevalence of the R145C variant was assessed worldwide in the "1000 Genomes Project" and in 1,012 whites and 1,226 African-Americans in New York, New York. The 1000 Genomes Project data demonstrated that the R145C polymorphism is rare in non-African-derived populations but present in 5% to 12% of Sub-Saharan African-derived populations. The R145C polymorphism was also rare in New York whites (1 of 1,012, 0.1%); however, strikingly, 53 of the 1,226 New York African-Americans (4.3%) were R145C heterozygotes. The lipid profiles of the Qatari and New York R145C heterozygotes were compared with those of controls. The Qatari R145C subjects had higher triglyceride levels than the Qatari controls (p <0.007) and the New York African-American R145C subjects had an average of 52% greater fasting triglyceride levels than the New York African-American controls (p <0.002). From these observations, likely millions of people worldwide derived from Sub-Saharan Africans are apolipoprotein E R145C. In conclusion, although larger epidemiologic studies are necessary to determine the long-term consequences of this polymorphism, the available evidence suggests it is a common cause of a mild triglyceride dyslipidemia.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
R145C is always in phase with APOE ε3 and R150H is always in phase with APOE ε2.
“Prior studies [7][8][9] and Alzheimer Disease Sequencing Project (ADSP) data have shown that R145C is always in phase with ε3 and R150H is always in phase with ε2.”
From Association of African Ancestry–Specific <i>APOE</i> Missense Variant R145C With Risk of Alzheimer Disease (2023) · cites this paper as [7]
The Results (page not provided) say that most African-American R145C variants were on the E3 allele, but identify one on an E4 allele. That counterexample contradicts the claim that R145C is always in phase with ε3. The retrieved passages do not address R150H phase. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe R145C mutant can result in altered function including mild triglyceride dyslipidemia.
“Other mutations like R145C mutant can results in altered function including mild triglyceride dyslipidemia [21].”
From Discovery of a Missense Mutation (Q222K) of the <i>APOE</i> Gene from the Australian Imaging, Biomarker and Lifestyle Study (2023) · cites this paper as [21]
APOE (Arg145Cys) heterozygotes in Africa-derived populations were associated with higher triglyceride levels.
“while APOE (Arg145Cys) heterozygotes in Africa-derived populations were associated with higher triglyceride levels64).”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [64]
APOE (Arg145Cys) was inherited dominantly with incomplete penetrance and was thought to be dependent on environmental factors.
“APOE (Arg145Cys) was inherited dominantly with incomplete penetrance and was thought to be dependent on environmental factors64, 65).”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [64]
More than 4% of individuals of African ancestry carry R145C, while it is very rare in people of European ancestry.
“More than 4% of individuals of African ancestry carry R145C, 7 while it is very rare in people of European ancestry (eTable 1 in Supplement 1).”
From Association of African Ancestry–Specific <i>APOE</i> Missense Variant R145C With Risk of Alzheimer Disease (2023) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.
Nakashima, Y., Plump, A. S., Raines, E. W., Breslow, J. L., & Ross, R. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.1.133 · Cited by 1,693 · see citing works
Rall, S. C., Weisgraber, K. H., Innerarity, T. L., & Mahley, R. W. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.15.4696 · Cited by 345 · see citing works
Wardell, M. R., Brennan, S. O., Janus, E. D., Fraser, R., & Carrell, R. W. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113096 · Cited by 159 · cited 5× · see citing works
“The R145C variant reduces the positive charge of this domain,(8,21) because it has 40% of the binding affinity of ApoE3 to the LDL receptor.(8,21) This discrepancy in disease manifestation might be explained by considering the role of other ApoE receptors in the clearance of remnant particles from the circulation, inc…”
InfluentialWardell, M. R., Weisgraber, K. H., Havekes, L. M., & Rall, S. C. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)30067-5 · Cited by 80 · see citing works
Pocovi, M., Cenarro, A., Civeir, F., Myers, R. H., Casao, E., Esteban, M., & Ordovas, J. M. (1996) · Atherosclerosis · doi:10.1016/0021-9150(95)06745-0 · Cited by 42 · see citing works
Mitani, A., Ishigami, M., Watase, K., Minakata, T., & Yamamura, T. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.7377 · Cited by 24 · see citing works
Flagged first, then by citations
Research works printed but not linked: 26
- [1]Davignon J Gregg RE Sing CF Apolipoprotein E polymorphism and atherosclerosis Arteriosclerosis 1988 8 1 21 3277611
- [2]Eichner JE Dunn ST Perveen G Thompson DM Stewart KE Stroehla BC Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review Am J Epidemiol 2002 155 487 495 11882522
- [3]Mahley RW Rall SC Jr Scriver CR Beaudet AL Sly WS Valle D Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism The Metabolic and Molecular Bases of Inherited Disease 7 New York McGraw-Hill 1995 1953 1980
- [4]Mahley RW Rall SC Jr Apolipoprotein E: far more than a lipid transport protein Annu Rev Genomics Hum Genet 2000 1 507 537 11701639
- [5]Hunter-Zinck H Musharoff S Salit J Al-Ali KA Chouchane L Gohar A Matthews R Butler MW Fuller J Hackett NR Crystal RG Clark AG Population genetic structure of the people of Qatar Am J Hum Genet 2010 87 17 25 20579625 PMC2896773
- [6]Bener A Zirie M Janahi IM Al-Hamaq AO Musallam M Wareham NJ Prevalence of diagnosed and undiagnosed diabetes mellitus and its risk factors in a population-based study of Qatar Diabetes Res Clin Pract 2009 84 99 106 19261345
- [7]de Villiers WJ van der Westhuyzen DR Coetzee GA Henderson HE Marais AD The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance Arterioscler Thromb Vasc Biol 1997 17 865 872 9157949
- [8]Ji ZS Fazio S Mahley RW Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia J Biol Chem 1994 269 13421 13428 8175773
- [9]Gerdes LU Gerdes C Hansen PS Klausen IC Faergeman O Dyerberg J The apolipoprotein E polymorphism in Greenland Inuit in its global perspective Hum Genet 1996 98 546 550 8882873
- [10]Feussner G Scharnagl H Scherbaum C Acar J Dobmeyer J Lohrmann J Wieland H Marz W Apolipoprotein E5 (Glu212-->Lys): increased binding to cell surface proteoglycans but decreased uptake and lysosomal degradation in cultured fibroblasts J Lipid Res 1996 37 1632 1645 8864947
- [11]Shore VG Shore B Heterogeneity of human plasma very low density lipoproteins. Separation of species differing in protein components Biochemistry 1973 12 502 507 4345806
- [12]Mahley RW Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer’s disease Isr J Med Sci 1996 32 414 429 8682647
- [13]Cullen P Cignarella A Brennhausen B Mohr S Assmann G von EA Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages J Clin Invest 1998 101 1670 1677 9541497 PMC508748
- [14]Smith JD Miyata M Ginsberg M Grigaux C Shmookler E Plump AS Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors J Biol Chem 1996 271 30647 30655 8940040
- [15]Riddell DR Graham A Owen JS Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease J Biol Chem 1997 272 89 95 8995232
- [16]Mistry MJ Clay MA Kelly ME Steiner MA Harmony JA Apolipoprotein E restricts interleukin-dependent T lymphocyte proliferation at the G1A/G1B boundary Cell Immunol 1995 160 14 23 7842480
- [17]Vogel T Guo NH Guy R Drezlich N Krutzsch HC Blake DA Panet A Roberts DD Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation J Cell Biochem 1994 54 299 308 8200910
- [19]Weisgraber KH Innerarity TL Mahley RW Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site J Biol Chem 1982 257 2518 2521 6277903
- [20]Rall SC Jr Mahley RW The role of apolipoprotein E genetic variants in lipoprotein disorders J Intern Med 1992 231 653 659 1619388
- [22]Raven P Johnson G Mason KA Losos JB Singer SS Genes within populations Biology 9 New York McGraw Hill 2010 401 402
- [23]Rizzo M Berneis K Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention? J Atheroscler Thromb 2005 12 237 239 16205019
- [24]Morganroth J Levy RI Fredrickson DS The biochemical, clinical, and genetic features of type III hyperlipoproteinemia Ann Intern Med 1975 82 158 174 163608
- [25]Grunfeld C Kotler DP Hamadeh R Tierney A Wang J Pierson RN Hypertriglyceridemia in the acquired immunodeficiency syndrome Am J Med 1989 86 27 31 2910092
- [26]Periard D Telenti A Sudre P Cheseaux JJ Halfon P Reymond MJ Marcovina SM Glauser MP Nicod P Darioli R Mooser V Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study Circulation 1999 100 700 705 10449690
- [29]Lohse P Rader DJ Brewer HB Jr Heterozygosity for apolipoprotein E-4Philadelphia(Glu13----Lys, Arg145----Cys) is associated with incomplete dominance of type III hyperlipoproteinemia J Biol Chem 1992 267 13642 13646 1352296
- [30]Lohse P Mann WA Stein EA Brewer HB Jr Apolipoprotein E-4Philadelphia (Glu13----Lys, Arg145----Cys). Homozygosity for two rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia J Biol Chem 1991 266 10479 10484 1674745
Cited by
Sorted by citations
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756 · see citing works
Le Guen, Y., Raulin, A.-C., Logue, M. W., Sherva, R., Belloy, M. E., Eger, S. J., Chen, A., Kennedy, G., Kuchenbecker, L., O’Leary, J. P., et al. (2023) · JAMA · doi:10.1001/jama.2023.0268 · Cited by 50 · see citing works
Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features
Matsunaga, A., & Saito, T. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65393 · Cited by 14 · see citing works
Roberts, B. R., Laffoon, S. B., Roberts, A. M., Porter, T., Fowler, C., Masters, C. L., Dratz, E. A., Laws, S. M., & for the AIBL research group (2023) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-220075 · Cited by 2 · see citing works
- Authors
- Abou Ziki, M. D., Strulovici-Barel, Y., Hackett, N. R., Rodriguez-Flores, J. L., Mezey, J. G., Salit, J., Radisch, S., Hollmann, C., Chouchane, L., Malek, J., Zirie, M. A., Jayyuosi, A., Gotto, A. M., & Crystal, R. G.
- Affiliations
- Weill Cornell Medicine (US)
- Cornell University (US)
- Weill Cornell Medical College in Qatar (QA)
- Hamad Medical Corporation (QA)
- Corresponding author
- Crystal, Ronald G.
- ORCID
- Venue
- The American Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 113
- Issue
- 2
- Pages
- 302-308
- ISSN
- 0002-9149 (ISSN-L)
- PMC
- PMC3943837
- OpenAlex
- W1971360302
- Cited by
- 21
- References
- 6
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 1 · 2017: 1 · 2016: 2 · 2015: 3 · 2014: 3
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The American Journal of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000457)
- National Heart, Lung, and Blood Institute (T32HL094284)
- National Center for Research Resources (UL1RR024996)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, type III hyperlipoproteinemia, prevalence, African Americans, sub-Saharan Africans, triglyceride levels, genetic variants, 1000 Genomes Project
- MeSH terms
- Alleles, Apolipoproteins E, Black or African American, DNA, Genotype, Humans, New York, Polymorphism, Genetic, Risk Factors, Prevalence, Polymerase Chain Reaction, Genetic Predisposition to Disease, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review